Vanda Pharmaceuticals (VNDA) Capital Expenditures Growth (5y) (2016 - 2026)
Vanda Pharmaceuticals (VNDA) Capital Expenditures Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - |
| 10 | Vanda Pharmaceuticals | 314.84 Mn | 112.53 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.20% |
| Dec 31, 2025 | -36.21% |
| Sep 30, 2025 | -8.13% |
| Jun 30, 2025 | 7.32% |
| Mar 31, 2025 | 3.17% |
| Dec 31, 2024 | 25.77% |
| Sep 30, 2024 | -11.35% |
| Jun 30, 2024 | -16.37% |
| Mar 31, 2024 | -55.32% |
| Dec 31, 2023 | 62.98% |
| Sep 30, 2023 | -29.31% |
| Jun 30, 2023 | -6.01% |
| Mar 31, 2023 | -17.69% |
| Dec 31, 2022 | 6.61% |
| Sep 30, 2022 | -16.79% |
| Jun 30, 2022 | -20.92% |
| Mar 31, 2022 | -30.96% |
| Dec 31, 2021 | -28.09% |
| Sep 30, 2021 | -15.06% |
| Dec 31, 2020 | 6.23% |